PACERONE Drug Patent Profile
✉ Email this page to a colleague
When do Pacerone patents expire, and what generic alternatives are available?
Pacerone is a drug marketed by Upsher Smith Labs and is included in one NDA.
The generic ingredient in PACERONE is amiodarone hydrochloride. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the amiodarone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pacerone
A generic version of PACERONE was approved as amiodarone hydrochloride by TEVA PHARMS on November 30th, 1998.
Summary for PACERONE
Recent Clinical Trials for PACERONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Population Health Research Institute | Phase 3 |
Rockefeller University | Phase 4 |
National Institute on Drug Abuse (NIDA) | Phase 4 |
Pharmacology for PACERONE
Anatomical Therapeutic Chemical (ATC) Classes for PACERONE
US Patents and Regulatory Information for PACERONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upsher Smith Labs | PACERONE | amiodarone hydrochloride | TABLET;ORAL | 075135-002 | Apr 12, 2005 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Upsher Smith Labs | PACERONE | amiodarone hydrochloride | TABLET;ORAL | 075135-001 | Apr 30, 1998 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Upsher Smith Labs | PACERONE | amiodarone hydrochloride | TABLET;ORAL | 075135-003 | Jul 2, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |